Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Immunotherapy: Personalized Treatment for Advanced Prostate Cancer

September 19th 2012

In April 2010, the FDA approved sipuleucel-T for patients with castration-resistant and metastatic prostate cancer, providing a new treatment that would help the body fight its own cancer.

Final Results of Abiraterone Acetate in Advanced Prostate Cancer Show Significantly Improved Survival

September 18th 2012

Abiraterone acetate significantly improved overall survival with positive responses seen in several subgroups of patients with metastatic castration-resistant prostate cancer.

Clinical Insights Into Genitourinary Cancer

September 12th 2012

A quick glance at a recent study examining the renal cell carcinoma immunotherapy AGS-003 and the FDA approval of a new noninvasive prostate health index test.

Dr. Petrylak Explains How Sipuleucel-T Impacts Survival

September 7th 2012

Dr. Daniel Petrylak, from the Smilow Cancer Center at Yale-New Haven, Explains the Correlation Between Immune Response to Sipuleucel-T and Survival.

“Male Lumpectomy” Emerges as New Option in Prostate Cancer: An Interview With E. David Crawford, MD

September 6th 2012

Targeted focal therapy offers some men with localized prostate cancer a solution between active surveillance and definitive treatment with surgery and/or radiation.

Enzalutamide Approved for Late-Stage Prostate Cancer

August 31st 2012

The FDA approved enzalutamide for use in patients with metastatic castration-resistant prostate cancer who have been previously treated with docetaxel and hormonal therapy.

Dr. Mohler Discusses Prostate Cancer Trial Endpoints

August 30th 2012

Dr. James Mohler, from Roswell Park Cancer Institute, Discusses the Need for Intermediate Endpoints for Early Stage Prostate Cancer Trials.

FDA Grants Priority Review to New Indication for Abiraterone Acetate

August 29th 2012

The FDA announced that Priority Review has been granted to abiraterone acetate for certain advanced prostate cancer cases based on positive data presented at the ASCO annual meeting.

Identification and Prevention of Skeletal-Related Events

August 27th 2012

Immunotherapy for Castration-Resistant Prostate Cancer

August 27th 2012

Optimal Treatment Sequencing for Advanced Prostate Cancer

August 27th 2012

Therapeutic Options for Advanced Prostate Cancer

August 27th 2012

Evidence-Based Care for Localized Prostate Cancer

August 27th 2012

Deciding Treatment Options for Early-Stage Prostate Cancer

August 27th 2012

Robotic-Assisted Laparoscopic Radical Prostatectomies

August 27th 2012

Prostate Cancer Screening and Early Detection, Part III

August 27th 2012

Prostate Cancer Screening and Early Detection, Part I

August 27th 2012

Prostate Cancer Screening and Early Detection, Part II

August 27th 2012

Researchers Determine Immune Parameters that Lead to Better Survival in Patients who Receive Sipuleucel-T

August 17th 2012

Researchers have determined that patients who received sipuleucel-T (Provenge, Dendreon) developed immune parameters that correlate to improved overall survival, giving researchers a better understanding of how the immunotherapy works at a cellular level to improve survival.

Newly Published Results Show Survival Benefit with Enzalutamide in Prostate Cancer

August 16th 2012

The novel drug enzalutamide (formerly MDV3100) significantly improved overall survival in men with metastatic castrate-resistant prostate cancer (mCRPC).